January 18, 2022
Steven D. Pearson
President
Institute for Clinical and Economic Review
14 Beacon Street, Suite 800,
Boston, MA 02108
Re: Draft Scoping Document for Beta-Amyloid Antibodies for Early Alzheimer’s Disease
Dear Mr. Pearson:
The American Geriatrics Society (AGS) greatly appreciates the opportunity to comment on the
draft scoping document outlining the assessment of beta-amyloid antibodies for the treatment of
Alzheimer’s disease (AD). The AGS is a nationwide, not-for-profit society of geriatrics
healthcare professionals dedicated to improving the health, independence, and quality of life of
older people. Our 6,000+ members include geriatricians, geriatrics nurse practitioners, social
workers, family practitioners, physician assistants, pharmacists, and internists who are pioneers
in advanced-illness care for older individuals, with a focus on championing interprofessional
teams, eliciting personal care goals, and treating older people as whole persons. The AGS
believes in a just society, one where we all are supported by and able to contribute to
communities where ageism, ableism, classism, homophobia, racism, sexism, xenophobia, and
other forms of bias and discrimination no longer impact healthcare access, quality, and outcomes
for older adults and their caregivers. The AGS advocates for policies and programs that support
the health, independence, and quality of life of all of us as we age.
We applaud the Institute for Clinical and Economic Review (ICER) for engaging stakeholders to
refine the scope of the assessment of donanemab and lecanemab for the treatment of early AD.
The AGS also supports a reassessment of aducanumab to update ICER’s evidence review should
new clinical evidence emerge. Given the heavy toll of AD on patients, caregivers, and their
families, it is crucial to evaluate the clinical evidence of these treatments and their safety and
effectiveness thoroughly.
The AGS appreciates the opportunity to review this draft scope and share our recommendations
which we hope you will consider as you move through the process of developing the evidence
report and presentation.
GENERAL COMMENT
The AGS recommends a revision of the fifth line on the second page, “…accumulate beta-
amyloid in the brain, which can be detected in the cerebrospinal fluid (CSF),” which implies that
individuals with AD have higher levels of beta-amyloid in the brain detected in the CSF.
However, the levels of beta-amyloid are lower in the CSF for people with AD as the disease
progresses.